Cancer

Title
A Study to Compare Radiotherapy Alone Versus Radiotherapy with Concurrent Chemotherapy (with the drug temozolomide) Versus Radiotherapy with Adjuvant Chemotherapy Versus Radiotherapy with Concurrent and Adjuvant Chemotherapy.
Trial Number
203666072011
Number of Participants
748
Principal Investigator

Edward Melian

M.D.
Radiation Oncology
Associate Professor
Eligibility

Patients must be histologically confirmed and newly diagnosed with anaplastic oligodendroglioma, anaplasticoligoastrocytoma or anaplastic astrocytoma by local diagnosis. Patients must have a complete medical history and physical examination, including neurological evaluation and vital signs, WHO performance status 0 - 2 and be = 18 years of age. Patients must have absence of any other serious medical condition that can interfere with follow-up or with oral medication intake and must have CBC, CMP and brain imaging.

Purpose

The purpose of this study is to determine whether the addition of temozolomide treatment to radiotherapy (concomitant treatment) or the addition of temozolomide treatment after completion of radiotherapy on five days out of every 28 days for 12 months (adjuvant treatment) will improve the results of the treatment. This study will find out what effects, good and/or bad, the addition of temozolomide has when it is given at the same time as radiotherapy, after radiotherapy or both.

Enrollment

(708) 216-2568

MORE CLINICAL TRIALS

Clinical Trials

For more information call (888) LUHS-888.